Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Cumulative risk analysis of carcinogenic contaminants in United States drinking water.

Evans S, Campbell C, Naidenko OV.

Heliyon. 2019 Sep 19;5(9):e02314. doi: 10.1016/j.heliyon.2019.e02314. eCollection 2019 Sep.

2.

Exposure-based assessment and economic valuation of adverse birth outcomes and cancer risk due to nitrate in United States drinking water.

Temkin A, Evans S, Manidis T, Campbell C, Naidenko OV.

Environ Res. 2019 Sep;176:108442. doi: 10.1016/j.envres.2019.04.009. Epub 2019 Jun 11.

3.

Applying a cumulative risk framework to drinking water assessment: a commentary.

Stoiber T, Temkin A, Andrews D, Campbell C, Naidenko OV.

Environ Health. 2019 Apr 30;18(1):37. doi: 10.1186/s12940-019-0475-5.

4.

Evidence-based toxicology for the 21st century: opportunities and challenges.

Stephens ML, Andersen M, Becker RA, Betts K, Boekelheide K, Carney E, Chapin R, Devlin D, Fitzpatrick S, Fowle JR 3rd, Harlow P, Hartung T, Hoffmann S, Holsapple M, Jacobs A, Judson R, Naidenko O, Pastoor T, Patlewicz G, Rowan A, Scherer R, Shaikh R, Simon T, Wolf D, Zurlo J.

ALTEX. 2013;30(1):74-103. doi: 10.14573/altex.2013.1.074.

5.

KLRG1 binds cadherins and preferentially associates with SHIP-1.

Tessmer MS, Fugere C, Stevenaert F, Naidenko OV, Chong HJ, Leclercq G, Brossay L.

Int Immunol. 2007 Apr;19(4):391-400. Epub 2007 Feb 16.

PMID:
17307799
6.

The complementarity determining region 2 of BV8S2 (V beta 8.2) contributes to antigen recognition by rat invariant NKT cell TCR.

Pyz E, Naidenko O, Miyake S, Yamamura T, Berberich I, Cardell S, Kronenberg M, Herrmann T.

J Immunol. 2006 Jun 15;176(12):7447-55.

7.

Costimulation through NKG2D enhances murine CD8+ CTL function: similarities and differences between NKG2D and CD28 costimulation.

Markiewicz MA, Carayannopoulos LN, Naidenko OV, Matsui K, Burack WR, Wise EL, Fremont DH, Allen PM, Yokoyama WM, Colonna M, Shaw AS.

J Immunol. 2005 Sep 1;175(5):2825-33.

8.

Expansion of human Valpha24+ NKT cells by repeated stimulation with KRN7000.

Rogers PR, Matsumoto A, Naidenko O, Kronenberg M, Mikayama T, Kato S.

J Immunol Methods. 2004 Feb 15;285(2):197-214.

PMID:
14980434
9.

Genetic control of NKT cell numbers maps to major diabetes and lupus loci.

Esteban LM, Tsoutsman T, Jordan MA, Roach D, Poulton LD, Brooks A, Naidenko OV, Sidobre S, Godfrey DI, Baxter AG.

J Immunol. 2003 Sep 15;171(6):2873-8.

10.

Genetically linked C-type lectin-related ligands for the NKRP1 family of natural killer cell receptors.

Iizuka K, Naidenko OV, Plougastel BF, Fremont DH, Yokoyama WM.

Nat Immunol. 2003 Aug;4(8):801-7. Epub 2003 Jul 13.

PMID:
12858173
11.

Surprisingly minor influence of TRAV11 (Valpha14) polymorphism on NK T-receptor mCD1/alpha-galactosylceramide binding kinetics.

Sim BC, Holmberg K, Sidobre S, Naidenko O, Niederberger N, Marine SD, Kronenberg M, Gascoigne NR.

Immunogenetics. 2003 Mar;54(12):874-83. Epub 2003 Feb 14.

PMID:
12671739
12.

The crystal structure of a TL/CD8alphaalpha complex at 2.1 A resolution: implications for modulation of T cell activation and memory.

Liu Y, Xiong Y, Naidenko OV, Liu JH, Zhang R, Joachimiak A, Kronenberg M, Cheroutre H, Reinherz EL, Wang JH.

Immunity. 2003 Feb;18(2):205-15.

13.

Natural killer cell-mediated lysis of dorsal root ganglia neurons via RAE1/NKG2D interactions.

Backström E, Chambers BJ, Ho EL, Naidenko OV, Mariotti R, Fremont DH, Yokoyama WM, Kristensson K, Ljunggren HG.

Eur J Immunol. 2003 Jan;33(1):92-100.

14.

Human invariant V alpha 24-J alpha Q TCR supports the development of CD1d-dependent NK1.1+ and NK1.1- T cells in transgenic mice.

Capone M, Cantarella D, Schümann J, Naidenko OV, Garavaglia C, Beermann F, Kronenberg M, Dellabona P, MacDonald HR, Casorati G.

J Immunol. 2003 Mar 1;170(5):2390-8.

15.
16.

Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer.

Kita H, Naidenko OV, Kronenberg M, Ansari AA, Rogers P, He XS, Koning F, Mikayama T, Van De Water J, Coppel RL, Kaplan M, Gershwin ME.

Gastroenterology. 2002 Oct;123(4):1031-43.

PMID:
12360465
17.

The V alpha 14 NKT cell TCR exhibits high-affinity binding to a glycolipid/CD1d complex.

Sidobre S, Naidenko OV, Sim BC, Gascoigne NR, Garcia KC, Kronenberg M.

J Immunol. 2002 Aug 1;169(3):1340-8.

18.

Recognition of a virus-encoded ligand by a natural killer cell activation receptor.

Smith HR, Heusel JW, Mehta IK, Kim S, Dorner BG, Naidenko OV, Iizuka K, Furukawa H, Beckman DL, Pingel JT, Scalzo AA, Fremont DH, Yokoyama WM.

Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8826-31. Epub 2002 Jun 11.

20.

Ligands for murine NKG2D display heterogeneous binding behavior.

Carayannopoulos LN, Naidenko OV, Kinder J, Ho EL, Fremont DH, Yokoyama W.

Eur J Immunol. 2002 Mar;32(3):597-605.

21.

Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis.

Jahng AW, Maricic I, Pedersen B, Burdin N, Naidenko O, Kronenberg M, Koezuka Y, Kumar V.

J Exp Med. 2001 Dec 17;194(12):1789-99.

22.

T cell responses modulated through interaction between CD8alphaalpha and the nonclassical MHC class I molecule, TL.

Leishman AJ, Naidenko OV, Attinger A, Koning F, Lena CJ, Xiong Y, Chang HC, Reinherz E, Kronenberg M, Cheroutre H.

Science. 2001 Nov 30;294(5548):1936-9.

23.

Natural killer T cells reactive to a single glycolipid exhibit a highly diverse T cell receptor beta repertoire and small clone size.

Matsuda JL, Gapin L, Fazilleau N, Warren K, Naidenko OV, Kronenberg M.

Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12636-41. Epub 2001 Oct 9.

24.

Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells.

Metelitsa LS, Naidenko OV, Kant A, Wu HW, Loza MJ, Perussia B, Kronenberg M, Seeger RC.

J Immunol. 2001 Sep 15;167(6):3114-22.

25.

Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes.

Sharif S, Arreaza GA, Zucker P, Mi QS, Sondhi J, Naidenko OV, Kronenberg M, Koezuka Y, Delovitch TL, Gombert JM, Leite-De-Moraes M, Gouarin C, Zhu R, Hameg A, Nakayama T, Taniguchi M, Lepault F, Lehuen A, Bach JF, Herbelin A.

Nat Med. 2001 Sep;7(9):1057-62.

PMID:
11533711
26.

The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice.

Hong S, Wilson MT, Serizawa I, Wu L, Singh N, Naidenko OV, Miura T, Haba T, Scherer DC, Wei J, Kronenberg M, Koezuka Y, Van Kaer L.

Nat Med. 2001 Sep;7(9):1052-6.

PMID:
11533710
27.

CD1d-restricted NKT cells: an interstrain comparison.

Hammond KJ, Pellicci DG, Poulton LD, Naidenko OV, Scalzo AA, Baxter AG, Godfrey DI.

J Immunol. 2001 Aug 1;167(3):1164-73.

28.

Cytometric and functional analyses of NK and NKT cell deficiencies in NOD mice.

Poulton LD, Smyth MJ, Hawke CG, Silveira P, Shepherd D, Naidenko OV, Godfrey DI, Baxter AG.

Int Immunol. 2001 Jul;13(7):887-96.

PMID:
11431419
29.

Right on target: novel approaches for the direct visualization of CD1-specific T cell responses.

Kronenberg M, Naidenko O, Koning F.

Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):2950-2. Review. No abstract available.

30.

Glycolipid antigen processing for presentation by CD1d molecules.

Prigozy TI, Naidenko O, Qasba P, Elewaut D, Brossay L, Khurana A, Natori T, Koezuka Y, Kulkarni A, Kronenberg M.

Science. 2001 Jan 26;291(5504):664-7.

31.

Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers.

Matsuda JL, Naidenko OV, Gapin L, Nakayama T, Taniguchi M, Wang CR, Koezuka Y, Kronenberg M.

J Exp Med. 2000 Sep 4;192(5):741-54.

32.

CD1-mediated antigen presentation of glycosphingolipids.

Naidenko OV, Koezuka Y, Kronenberg M.

Microbes Infect. 2000 May;2(6):621-31. Review.

PMID:
10884613
33.

Membrane lymphotoxin is required for the development of different subpopulations of NK T cells.

Elewaut D, Brossay L, Santee SM, Naidenko OV, Burdin N, De Winter H, Matsuda J, Ware CF, Cheroutre H, Kronenberg M.

J Immunol. 2000 Jul 15;165(2):671-9.

34.

Binding and antigen presentation of ceramide-containing glycolipids by soluble mouse and human CD1d molecules.

Naidenko OV, Maher JK, Ernst WA, Sakai T, Modlin RL, Kronenberg M.

J Exp Med. 1999 Oct 18;190(8):1069-80.

35.

Syntheses of biotinylated alpha-galactosylceramides and their effects on the immune system and CD1 molecules.

Sakai T, Naidenko OV, Iijima H, Kronenberg M, Koezuka Y.

J Med Chem. 1999 May 20;42(10):1836-41.

PMID:
10346936
36.

Structural requirements for galactosylceramide recognition by CD1-restricted NK T cells.

Brossay L, Naidenko O, Burdin N, Matsuda J, Sakai T, Kronenberg M.

J Immunol. 1998 Nov 15;161(10):5124-8.

Supplemental Content

Loading ...
Support Center